JP2008535916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535916A5 JP2008535916A5 JP2008506574A JP2008506574A JP2008535916A5 JP 2008535916 A5 JP2008535916 A5 JP 2008535916A5 JP 2008506574 A JP2008506574 A JP 2008506574A JP 2008506574 A JP2008506574 A JP 2008506574A JP 2008535916 A5 JP2008535916 A5 JP 2008535916A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- heterocyclyl
- aralkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 182
- 125000003118 aryl group Chemical group 0.000 claims 179
- 125000000623 heterocyclic group Chemical group 0.000 claims 164
- 125000003710 aryl alkyl group Chemical group 0.000 claims 162
- 125000000217 alkyl group Chemical group 0.000 claims 154
- 125000000753 cycloalkyl group Chemical group 0.000 claims 128
- 229910052739 hydrogen Inorganic materials 0.000 claims 114
- 239000001257 hydrogen Substances 0.000 claims 114
- 125000001188 haloalkyl group Chemical group 0.000 claims 101
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 89
- 150000002431 hydrogen Chemical class 0.000 claims 88
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 87
- 125000004093 cyano group Chemical group *C#N 0.000 claims 85
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 76
- 125000005843 halogen group Chemical group 0.000 claims 59
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 55
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 55
- 125000003342 alkenyl group Chemical group 0.000 claims 39
- 125000000304 alkynyl group Chemical group 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 37
- 229910052757 nitrogen Inorganic materials 0.000 claims 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 26
- 125000004450 alkenylene group Chemical group 0.000 claims 22
- 125000002947 alkylene group Chemical group 0.000 claims 22
- 125000004419 alkynylene group Chemical group 0.000 claims 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000000262 haloalkenyl group Chemical group 0.000 claims 19
- 125000004438 haloalkoxy group Chemical group 0.000 claims 19
- -1 aralkenyl Chemical group 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 3
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 230000004941 influx Effects 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- FJQFHTVTRAQBQI-UHFFFAOYSA-N 1'-pentylspiro[6h-furo[2,3-f][1,3]benzodioxole-7,3'-pyrrolo[2,3-b]pyridine]-2'-one Chemical compound C12=CC=CN=C2N(CCCCC)C(=O)C11C2=CC(OCO3)=C3C=C2OC1 FJQFHTVTRAQBQI-UHFFFAOYSA-N 0.000 claims 1
- LTQRQUSEENKDEL-UHFFFAOYSA-N 1'-pentylspiro[6h-furo[2,3-f][1,3]benzodioxole-7,3'-pyrrolo[3,2-b]pyridine]-2'-one Chemical compound C12=NC=CC=C2N(CCCCC)C(=O)C11C2=CC(OCO3)=C3C=C2OC1 LTQRQUSEENKDEL-UHFFFAOYSA-N 0.000 claims 1
- YKYKMOLNWHNSSJ-UHFFFAOYSA-N 1'-pentylspiro[6h-furo[2,3-f][1,3]benzodioxole-7,3'-pyrrolo[3,2-c]pyridine]-2'-one Chemical compound C12=CN=CC=C2N(CCCCC)C(=O)C11C2=CC(OCO3)=C3C=C2OC1 YKYKMOLNWHNSSJ-UHFFFAOYSA-N 0.000 claims 1
- YAVXCTQVGCPGJE-UHFFFAOYSA-N 4'-pentylspiro[6h-furo[2,3-f][1,3]benzodioxole-7,6'-thieno[3,2-b]pyrrole]-5'-one Chemical compound C1OC2=CC=3OCOC=3C=C2C21C(=O)N(CCCCC)C1=C2SC=C1 YAVXCTQVGCPGJE-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020844 Hyperthermia malignant Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 claims 1
- 208000026709 Liddle syndrome Diseases 0.000 claims 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010037113 Pseudoaldosteronism Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 206010040744 Sinus headache Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000007004 malignant hyperthermia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 0 *c1c(*)c(*=*)c(C(C**C2)(C(C(C3)C3CCC*(CC3)I)C3N3*)C3=O)c2c1* Chemical compound *c1c(*)c(*=*)c(C(C**C2)(C(C(C3)C3CCC*(CC3)I)C3N3*)C3=O)c2c1* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67096205P | 2005-04-11 | 2005-04-11 | |
| PCT/US2006/013318 WO2006110654A1 (en) | 2005-04-11 | 2006-04-11 | Spiroheterocyclic compounds and their uses as therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535916A JP2008535916A (ja) | 2008-09-04 |
| JP2008535916A5 true JP2008535916A5 (enExample) | 2009-04-02 |
Family
ID=36694990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506574A Pending JP2008535916A (ja) | 2005-04-11 | 2006-04-11 | スピロ複素環化合物および治療剤としてのその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7799798B2 (enExample) |
| EP (1) | EP1888592B1 (enExample) |
| JP (1) | JP2008535916A (enExample) |
| KR (1) | KR20080007250A (enExample) |
| CN (2) | CN101166744A (enExample) |
| AR (1) | AR053710A1 (enExample) |
| AT (1) | ATE504587T1 (enExample) |
| AU (1) | AU2006235329B2 (enExample) |
| BR (1) | BRPI0608995A2 (enExample) |
| CA (1) | CA2604010A1 (enExample) |
| DE (1) | DE602006021169D1 (enExample) |
| EC (1) | ECSP077848A (enExample) |
| ES (1) | ES2362908T3 (enExample) |
| HR (1) | HRP20070499A2 (enExample) |
| IL (1) | IL186615A0 (enExample) |
| MA (1) | MA29685B1 (enExample) |
| MX (1) | MX2007012637A (enExample) |
| MY (1) | MY145694A (enExample) |
| NO (1) | NO20074620L (enExample) |
| NZ (1) | NZ561204A (enExample) |
| PL (1) | PL1888592T3 (enExample) |
| RU (1) | RU2428424C2 (enExample) |
| SG (1) | SG161264A1 (enExample) |
| TN (1) | TNSN07384A1 (enExample) |
| TW (1) | TW200720278A (enExample) |
| WO (1) | WO2006110654A1 (enExample) |
| ZA (1) | ZA200709004B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| WO2008046065A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
| AU2007307638A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| CA2666136A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| CN103271906A (zh) * | 2006-10-12 | 2013-09-04 | 泽农医药公司 | 螺-吲哚酮化合物作为治疗剂的用途 |
| WO2008046082A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| WO2008046087A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| US20100010092A1 (en) * | 2006-12-19 | 2010-01-14 | Arless Ltd. | Use of modafinil to treat restless leg syndrome |
| US7795228B2 (en) * | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
| CA2685942A1 (en) * | 2007-05-16 | 2008-11-27 | Merck & Co., Inc. | Spiroindalones |
| US8273749B2 (en) * | 2007-10-04 | 2012-09-25 | Merck Sharp & Dohme Corp. | N-substituted oxindoline derivatives as calcium channel blockers |
| EP2205079A4 (en) | 2007-10-04 | 2010-10-27 | Merck Sharp & Dohme | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| SI2285808T1 (sl) | 2008-04-29 | 2014-03-31 | Novartis Ag | Spiro-indolni derivati za zdravljenje parazitskih bolezni |
| SMT201600475T1 (it) | 2008-08-22 | 2017-03-08 | Theracos Sub Llc | Procedimenti per la preparazione di inibitori di sglt2. |
| US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN103664973B (zh) * | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| WO2010053998A1 (en) * | 2008-11-05 | 2010-05-14 | Xenon Pharmaceuticals, Inc. | Spiro-condensed indole derivatives as sodium channel inhibitors |
| WO2010078307A1 (en) * | 2008-12-29 | 2010-07-08 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US8445696B2 (en) | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| BR112012021086A2 (pt) | 2010-02-26 | 2016-05-17 | Xenon Pharmaceuticals Inc | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| WO2013154712A1 (en) | 2012-04-12 | 2013-10-17 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| US9840513B2 (en) * | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| EP4536660A1 (en) * | 2022-06-09 | 2025-04-16 | GlaxoSmithKline Intellectual Property Development Ltd | Nitrogen containing condensed 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3189617A (en) | 1961-02-03 | 1965-06-15 | Sterling Drug Inc | 1-aryloxindoles and their preparation |
| DE1956237A1 (de) | 1969-11-08 | 1971-05-13 | Basf Ag | Spiro-pyrrolizidon-oxindole |
| DE2113343A1 (de) | 1971-03-19 | 1972-09-21 | Thiemann Chem Pharm Fab | Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung |
| US3723459A (en) | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| SE400966B (sv) | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
| US4670566A (en) | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4440785A (en) | 1980-10-30 | 1984-04-03 | A. H. Robins Company, Inc. | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation |
| US4438130A (en) * | 1981-11-12 | 1984-03-20 | The Upjohn Company | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds |
| JPS60142984A (ja) | 1983-12-28 | 1985-07-29 | Kyorin Pharmaceut Co Ltd | 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法 |
| US4569942A (en) | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
| JPS6130554A (ja) * | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
| US4690943A (en) | 1984-09-19 | 1987-09-01 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
| US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
| DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
| EP0299914B2 (de) * | 1987-07-17 | 2003-04-23 | Schering Aktiengesellschaft | 9-Halogen-(Z)-prostaglandinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5182289A (en) | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
| ES2110965T3 (es) | 1989-07-25 | 1998-03-01 | Taiho Pharmaceutical Co Ltd | Derivado de oxoindol. |
| DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5023265A (en) | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
| US5484778C1 (en) | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
| CA2095718A1 (en) | 1990-11-22 | 1992-05-23 | Hans-Rudolf Waespe | Isonicotinic acid derivatives and related spiro compounds with herbicidal action |
| US5116854A (en) | 1991-06-28 | 1992-05-26 | Pfizer Inc. | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| JPH08503450A (ja) | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド） |
| US5278162A (en) | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
| US5296478A (en) | 1992-10-07 | 1994-03-22 | The Dupont Merck Pharmaceutical Co. | 1-substituted oxindoles as cognition enhancers |
| US5776936A (en) | 1992-11-13 | 1998-07-07 | Pharmacia & Upjohn Company | Marcfortine/paraherquamide derivatives useful as antiparasitic agents |
| DE4242451A1 (de) | 1992-12-16 | 1994-06-23 | Basf Ag | Verfahren zur Herstellung von 5-Ringheterocyclen |
| US5298522A (en) | 1993-01-22 | 1994-03-29 | Pfizer Inc. | 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio |
| FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
| AT400950B (de) | 1994-02-04 | 1996-04-25 | Immodal Pharmaka Gmbh | Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen |
| US5763471A (en) | 1994-04-07 | 1998-06-09 | Cemaf | Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products |
| US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
| FR2722195B1 (fr) | 1994-07-07 | 1996-08-23 | Adir | Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
| CA2235686C (en) | 1995-10-24 | 2007-06-26 | Sanofi | Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them |
| HUP9600855A3 (en) | 1996-04-03 | 1998-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tenidap |
| JPH1095766A (ja) | 1996-09-19 | 1998-04-14 | Sanwa Kagaku Kenkyusho Co Ltd | アセトアミド誘導体、及びその用途 |
| FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
| ATE467418T1 (de) | 1997-01-20 | 2010-05-15 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
| NO317155B1 (no) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| EP1008588B1 (en) * | 1997-02-10 | 2003-04-16 | Ono Pharmaceutical Co., Ltd. | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient |
| JP2001524124A (ja) | 1997-05-07 | 2001-11-27 | ガレン（ケミカルズ）リミティド | テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具 |
| DE69821987T2 (de) * | 1997-12-25 | 2004-12-16 | Ono Pharmaceutical Co. Ltd. | Omega-cycloalkyl-prostaglandin e2 derivate |
| JP4087938B2 (ja) * | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
| EE04548B1 (et) * | 1998-04-01 | 2005-10-17 | Nortran Pharmaceuticals Inc. | Aminotskloheksleeterhendid, nende kompositsioonid ja nende kasutamine |
| US20040038970A1 (en) | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
| US6235780B1 (en) * | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| WO2000006556A1 (en) | 1998-07-27 | 2000-02-10 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| CA2373990C (en) | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| EP1399155B1 (en) | 1999-07-21 | 2008-05-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| EP1330426A4 (en) | 2000-10-13 | 2005-09-14 | Bristol Myers Squibb Co | SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE |
| DE60120748T2 (de) | 2000-11-10 | 2007-05-16 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindolderivate als beta-3-agonisten |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US20030078278A1 (en) | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
| JP2005507872A (ja) | 2001-08-14 | 2005-03-24 | イーライ・リリー・アンド・カンパニー | ３−置換オキシインドールβ３アゴニスト |
| EP1451173A4 (en) | 2001-11-01 | 2005-10-26 | Icagen Inc | PIPERIDINE |
| WO2003037274A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| EP1448560B1 (en) | 2001-11-20 | 2005-06-15 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| JP2005519921A (ja) | 2002-01-28 | 2005-07-07 | ファイザー株式会社 | Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物 |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| WO2003078394A1 (en) | 2002-03-15 | 2003-09-25 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
| AU2003245637A1 (en) | 2002-06-25 | 2004-01-06 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| CN1662206A (zh) | 2002-06-25 | 2005-08-31 | 惠氏公司 | 硫代－2－羟基吲哚衍生物在治疗皮肤病中的用途 |
| US7256218B2 (en) | 2002-11-22 | 2007-08-14 | Jacobus Pharmaceutical Company, Inc. | Biguanide and dihydrotriazine derivatives |
| US7182735B2 (en) * | 2003-02-26 | 2007-02-27 | Scimed Life Systems, Inc. | Elongated intracorporal medical device |
| CA2525866A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Treatment of psychotic and depressive disorders |
| CA2625837A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
| JP2007516955A (ja) | 2003-05-16 | 2007-06-28 | ファイザー・プロダクツ・インク | 双極性障害および関連症候の治療 |
| MXPA05012392A (es) | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamientos de ansiedad con ziprasidona. |
| BRPI0412348A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | derivados de piperazina e seu uso como agentes terapêuticos |
| DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
| WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| JPWO2005035498A1 (ja) | 2003-10-08 | 2006-12-21 | 住友製薬株式会社 | 含窒素二環性化合物の摂食調節剤としての用途 |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| GB0406867D0 (en) | 2004-03-26 | 2004-04-28 | F2G Ltd | Antifungal agents |
| BRPI0509307A (pt) | 2004-03-29 | 2007-09-04 | Pfizer | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 |
| GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| US8211883B2 (en) | 2004-04-01 | 2012-07-03 | Case Western Reserve University | Topical delivery of phthalocyanines |
| BRPI0509745A (pt) | 2004-04-08 | 2007-09-25 | Topotarget As | compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer |
| WO2005104711A2 (en) | 2004-04-27 | 2005-11-10 | Wyeth | Purification of progesterone receptor modulators |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| JP2007537235A (ja) | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療用ピリミジン誘導体 |
| US20050288317A1 (en) | 2004-06-24 | 2005-12-29 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
| GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| JP4677323B2 (ja) | 2004-11-01 | 2011-04-27 | キヤノン株式会社 | 画像処理装置及び画像処理方法 |
| CN101103016A (zh) | 2004-11-18 | 2008-01-09 | 因塞特公司 | 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法 |
| DE102005007694A1 (de) | 2005-02-18 | 2006-09-21 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| KR100944301B1 (ko) | 2005-02-22 | 2010-02-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｍｄｍ２의 소분자 억제제 및 이의 용도 |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| CN101166722A (zh) | 2005-04-29 | 2008-04-23 | 惠氏公司 | 制备3,3-二取代的羟吲哚和硫代羟吲哚的方法 |
| WO2006125048A2 (en) * | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| EP1924264B9 (en) * | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2008046087A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| WO2008046084A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| AU2007307638A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| CA2666136A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| CN103271906A (zh) | 2006-10-12 | 2013-09-04 | 泽农医药公司 | 螺-吲哚酮化合物作为治疗剂的用途 |
| WO2008046065A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN103664973B (zh) * | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US8445696B2 (en) * | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
-
2006
- 2006-04-10 AR ARP060101419A patent/AR053710A1/es unknown
- 2006-04-10 MY MYPI20061651A patent/MY145694A/en unknown
- 2006-04-11 ZA ZA200709004A patent/ZA200709004B/xx unknown
- 2006-04-11 DE DE602006021169T patent/DE602006021169D1/de active Active
- 2006-04-11 JP JP2008506574A patent/JP2008535916A/ja active Pending
- 2006-04-11 CN CNA2006800118134A patent/CN101166744A/zh active Pending
- 2006-04-11 BR BRPI0608995-0A patent/BRPI0608995A2/pt not_active IP Right Cessation
- 2006-04-11 HR HR20070499A patent/HRP20070499A2/xx not_active Application Discontinuation
- 2006-04-11 CN CN2010102862777A patent/CN101967150A/zh active Pending
- 2006-04-11 MX MX2007012637A patent/MX2007012637A/es active IP Right Grant
- 2006-04-11 TW TW095112908A patent/TW200720278A/zh unknown
- 2006-04-11 KR KR1020077026138A patent/KR20080007250A/ko not_active Ceased
- 2006-04-11 NZ NZ561204A patent/NZ561204A/en not_active IP Right Cessation
- 2006-04-11 AT AT06740804T patent/ATE504587T1/de not_active IP Right Cessation
- 2006-04-11 PL PL06740804T patent/PL1888592T3/pl unknown
- 2006-04-11 RU RU2007141633/04A patent/RU2428424C2/ru not_active IP Right Cessation
- 2006-04-11 WO PCT/US2006/013318 patent/WO2006110654A1/en not_active Ceased
- 2006-04-11 ES ES06740804T patent/ES2362908T3/es active Active
- 2006-04-11 AU AU2006235329A patent/AU2006235329B2/en not_active Expired - Fee Related
- 2006-04-11 SG SG201002516-1A patent/SG161264A1/en unknown
- 2006-04-11 EP EP06740804A patent/EP1888592B1/en not_active Not-in-force
- 2006-04-11 CA CA002604010A patent/CA2604010A1/en not_active Abandoned
- 2006-04-11 US US11/402,200 patent/US7799798B2/en not_active Expired - Fee Related
-
2007
- 2007-09-12 NO NO20074620A patent/NO20074620L/no not_active Application Discontinuation
- 2007-10-10 TN TNP2007000384A patent/TNSN07384A1/en unknown
- 2007-10-11 IL IL186615A patent/IL186615A0/en unknown
- 2007-10-30 EC EC2007007848A patent/ECSP077848A/es unknown
- 2007-10-30 MA MA30345A patent/MA29685B1/fr unknown
-
2010
- 2010-08-12 US US12/855,514 patent/US20120035199A9/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535916A5 (enExample) | ||
| JP2010506853A5 (enExample) | ||
| RU2007141633A (ru) | Спирогетероциклические соединения и их применение в качестве терапевтических средств | |
| JP2012532107A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| EP2306994B1 (en) | S1p1 receptor agonists and use thereof | |
| HRP20160732T1 (hr) | Enantiomeri spirooksindolskih spojeva i njihova upotreba kao terapijska sredstva | |
| US20100216762A1 (en) | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | |
| RU2009117605A (ru) | ПРОИЗВОДНЫЕ СПИРО-(ФУРО[3,2-c]ПИРИДИН-3-3'-ИНДОЛ)-2'(1'H)-ОНА И РОДСТВЕННЫЕ ИМ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ НАТРИЕВЫМИ КАНАЛАМИ ЗАБОЛЕВАНИЙ, ТАКИХ КАК БОЛЬ | |
| JP2009530237A (ja) | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 | |
| KR20230047425A (ko) | 항혈소판 약물 및 이의 용도 | |
| WO2017001307A1 (en) | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | |
| KR20240019389A (ko) | RORγ의 억제를 위한 피리미딘 삼환형 에논 유도체 및 다른 용도 | |
| KR20200006125A (ko) | 키나아제 억제제 및 이의 용도 | |
| TW202227435A (zh) | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物 | |
| US20070066640A1 (en) | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | |
| BR112014023957B1 (pt) | Compostos agonistas dos receptores adrenérgicos alfa-2 e composição farmacêutica que compreende os mesmos | |
| AU2017359773A1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| KR101494919B1 (ko) | 2환식 복소환 화합물 | |
| JP2025516719A (ja) | Ｎｌｒｐ３を阻害するためのオキソインドリニルアミド誘導体およびその使用 | |
| JP2006528691A (ja) | 細胞傷害性インデノおよびイソインドロイソキノロン | |
| KR900005011B1 (ko) | 5-아실-2-(1h)-피리디논 및 그의 제조방법 | |
| KR20230145089A (ko) | 단백질 포스파타제 2a(pp2a)의 치환된 사이클릭 조절인자 및 이를 사용하는 방법 | |
| KR20250164848A (ko) | Kcc2 강화제 및 이의 용도 | |
| JP2021500416A (ja) | 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体 |